The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Open accessAbstract
BACKGROUND: Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-negative breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until disease progression or an unacceptable level of toxic effects occurred. Stratification factors were the receipt or nonreceipt of neoadjuvant or adjuvant taxane therapy, the presence or absence of liver metastases at baseline, and programmed death ligand 1 (PD-L1) expression at baseline (positive vs. negative). The two primary end points were progression-free survival (in the intention-to-treat population and PD-L1-positive subgroup) and overall survival (tested in the intention-to-treat population; if the finding was significant, then it would be tested in the PD-L1-positive subgroup). RESULTS: Each group included 451 patients (median follow-up, 12.9 months). In the intention-to-treat analysis, the median progression-free survival was 7.2 months with atezolizumab plus nab-paclitaxel, as compared with 5.5 months with placebo plus nab-paclitaxel (hazard ratio for progression or death, 0.80; 95% confidence interval [CI], 0.69 to 0.92; P=0.002); among patients with PD-L1-positive tumors, the median progression-free survival was 7.5 months and 5.0 months, respectively (hazard ratio, 0.62; 95% CI, 0.49 to 0.78; P<0.001). In the intention-to-treat analysis, the median overall survival was 21.3 months with atezolizumab plus nab-paclitaxel and 17.6 months with placebo plus nab-paclitaxel (hazard ratio for death, 0.84; 95% CI, 0.69 to 1.02; P=0.08); among patients with PD-L1-positive tumors, the median overall survival was 25.0 months and 15.5 months, respectively (hazard ratio, 0.62; 95% CI, 0.45 to 0.86). No new adverse effects were identified. Adverse events that led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel. CONCLUSIONS: Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, PD-L1 status by SP142 is the companion test for the use of atezolizumab in combination with a taxane for first-line therapy in triple-negative ABC, with a cut-off of 1% positive staining on immune cells.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an analysis was conducted and presented, and showed an OS of 25 months versus 15.1 months favouring the atezolizumab arm.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PD-L1 positive group, atezolizumab provided a PFS benefit of 7.5 versus 5 months with a HR of 0.62 (95% CI 0.49-0.78, P < 0.001).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“In the ITT population, atezolizumab provided a benefit in PFS of 7.2 versus 5.5 months with a HR of 0.8 (95% CI 0.69-0.92, P = 0.002).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“In the ITT population, there was no significant benefit in OS with the addition of atezolizumab; median OS was 21.3 months versus 17.6 months (HR 0.84; 95% CI 0.69-1.02, P = 0.08).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [68]
In the citing paper
“to date, atezolizumab, in combination with chemotherapy, has been approved by the FDA for the treatment of squamous and nonsquamous NSCLC, small cell lung cancer, and PD-L1-positive triple-negative breast cancer (66)(67)(68)(69).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G. D., Goldstein, N. S., Hayes, M. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,217
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F. M., Poortmans, P. M., Rutgers, E. J. T., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,660
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Eenoo, F. V., Rouas, G., Francis, P. A., Crown, J. P., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,658
Self-citationPD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,420
Research works printed but not linked: 1
- Adams S Diamond JR Hamilton E et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol (in press).
Cited by
Sorted by citations
Items 901–1,000 of 1,010
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis
Latif, F., Jabbar, H. B. A., MALIK, H., Sadaf, H., Sarfraz, A., Sarfraz, Z., & Chérrez-Ojeda, I. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2023011 · Cited by 45
Sivakumar, S., Jin, D. X., Tukachinsky, H., Murugesan, K., McGregor, K., Danziger, N. A., Pavlick, D. C., Gjoerup, O. V., Ross, J. S., Harmon, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35245-x · Cited by 47
Self-citationImmunotherapy in breast cancer: current landscape and emerging trends
Ran, R., Chen, X., Yang, J., & Xu, B. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00667-y · Cited by 60
Onesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46
T-cell-based breast cancer immunotherapy
Pilipow, K., Darwich, A., & Losurdo, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.019 · Cited by 44
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
Li, L., Li, G., Rao, B., Dong, A.-H., Liang, W., Zhu, J., Qin, M.-P., Huang, W., Lu, J., Li, Z.-F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72649-5 · Cited by 46
Yuan, Y., Lee, J. S., Yost, S. E., Li, S. M., Frankel, P. H., Ruel, C., Schmolze, D. D., Robinson, K., Tang, A., Martínez, N., et al. (2020) · The Oncologist · doi:10.1002/onco.13574 · Cited by 45
Xie, W., Zhao, H., Wang, F., Wang, Y., He, Y. Z., Wang, T., Zhang, K., Yang, H., Zhou, Z., Shi, H., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01800-x · Cited by 45
Sinn, B. V., Loibl, S., Hanusch, C. A., Zahm, D.-M., Sinn, H., Untch, M., Weber, K. E., Karn, T., Becker, C., Marmé, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3113 · Cited by 45
Wang, X., Feng, M., Xiao, T., Guo, B., Liu, D., Liu, C., Pei, J., Liu, Q., Xiao, Y. Q., Rosin‐Arbesfeld, R., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01756-y · Cited by 46
Wu, T., Tang, C., Tao, R., Yong, X., Jiang, Q., & Feng, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693881 · Cited by 45
Wang, J., Browne, L. H., Šlapetová, I., Shang, F., Lee, K., Lynch, J., Beretov, J., Whan, R. M., Graham, P., & Millar, E. K. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-01116-6 · Cited by 47
Ni, Y., Tsang, J. Y., Shao, Y., Poon, I. K., Tam, F. K. Y., Shea, K.-H., & Tse, G. M.-K. (2022) · The Oncologist · doi:10.1093/oncolo/oyab063 · Cited by 45
Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
Chaudhuri, A., Kumar, D. N., Dehari, D., Singh, S. P., Kumar, P., Bolla, P. K., Kumar, D. K., & Agrawal, A. K. (2022) · Pharmaceuticals · doi:10.3390/ph15050542 · Cited by 51
Thompson, K. J., Leon-Ferre, R. A., Sinnwell, J. P., Zahrieh, D., Suman, V. J., Metzger, O., Asad, S., Stover, D. G., Carey, L., Sikov, W. M., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac018 · Cited by 45
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer
Mahtani, R. L., Kittaneh, M., Kalinsky, K. M., Mamounas, E. P., Badve, S., Vogel, C. L., Lower, E. E., Schwartzberg, L. S., & Pegram, M. D. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.12.011 · Cited by 45
Bergeron, A., MacGrogan, G. M., Bertaut, A., Ladoire, S., Arveux, P., Desmoulins, I., Bonnefoi, H. R., Loustalot, C., Auriol, S., Beltjens, F., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00742-9 · Cited by 44
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
Gámez-Chiachio, M., Sarrió, D., & Moreno‐Bueno, G. (2022) · Cancers · doi:10.3390/cancers14184543 · Cited by 49
Shi, W., Chen, Z., Liu, H., Chen, M., Feng, R., Wang, G., Chen, G., Chen, Z., Fan, P., Pang, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937125 · Cited by 44
“Retrospective studies have shown that patients with breast cancer with higher levels of stromal-infiltrating immune cells generally have longer progression-free survival (PFS) and overall survival (OS) (12, 13), and the results of immune checkpoint inhibitor (ICI) therapies for TNbreast cancer are encouraging (14, 15).”
BackgroundLymph nodes: at the intersection of cancer treatment and progression
Reticker-Flynn, N. E., & Engleman, E. G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.04.001 · Cited by 45
Guo, P., Huang, J., Zhu, B., Huang, A. C., Jiang, L., Fang, J., & Moses, M. A. (2023) · Science Advances · doi:10.1126/sciadv.abq7866 · Cited by 44
Zhang, Z., Pan, Q., Lu, M., & Zhao, B. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102156 · Cited by 46
Tang, Y., Wang, Z., & Li, Q. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202405367 · Cited by 44
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
Mina, L. A., Lim, S., Bahadur, S. W., & Firoz, A. T. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s184710 · Cited by 56
Yong, K. W., Yuen, D., Chen, M. Z., & Johnston, A. P. R. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b20993 · Cited by 48
Ho, A. Y., Wright, J. L., Blitzblau, R. C., Mutter, R. W., Duda, D. G., Norton, L., Bardia, A., Spring, L. M., Isakoff, S. J., Chen, J. H., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.011 · Cited by 45
The evolving management of metastatic triple negative breast cancer
Malhotra, M. K., & Emens, L. A. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.005 · Cited by 41
Self-citationPrognostic and predictive parameters in breast pathology: a pathologist's primer
Allison, K. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-00704-7 · Cited by 46
Advances in Combining Radiation and Immunotherapy in Breast Cancer
Nguyen, A. T., Shiao, S. L., & McArthur, H. L. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.03.007 · Cited by 46
Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma
Liu, Z., Wang, H., Hu, C., Wu, C., Wang, J., Hu, F., Fu, Y., Wen, J., & Zhang, W. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03449-6 · Cited by 45
Waks, A. G., Keenan, T. E., Li, T., Tayob, N., Wulf, G. M., Richardson, E. T., Attaya, V., Anderson, L., Mittendorf, E. A., Overmoyer, B. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005119 · Cited by 45
Self-citationTumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
Luque, M., Sanz-Álvarez, M., Morales-Gallego, M., Madoz‐Gúrpide, J., Zazo, S., Domínguez, C., Cazorla, A., Izarzugaza, Y., Arranz, J. L., Cristóbal, I., et al. (2022) · Cancers · doi:10.3390/cancers14246034 · Cited by 44
“The immune checkpoint inhibitors atezolizumab and pembrolizumab, both PD-1/PDL1 axis inhibitors, have been recently approved by the FDA for the treatment of unresectable, locally advanced or metastatic TN breast cancer [111,112].”
BackgroundRole Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer
Zhou, W., Lim, A., Edderkaoui, M., Osipov, A., Wu, H., Wang, Q., & Pandol, S. J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83586 · Cited by 49
Zheng, R., Liu, X., Zhang, Y., Liu, Y., Wang, Y.-P., Guo, S., Jin, X., Zhang, J., Guan, Y., & Liu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383978 · Cited by 44
“Although research on the use of atezolizumab for pancreatic cancer is limited, the agent has shown promising ef fi cacy in other tumor types including, metastatic breast cancer (77), and advanced alveolar soft part sarcoma (78).”
BackgroundZhu, B., Cai, Y., Zhou, L., Zhao, L., Chen, J., Shan, X., Sun, X., You, Q., Gong, X., Zhang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55904-z · Cited by 48
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 48
Wang, D., Gendoo, D. M. A., Ben‐David, Y., Woodgett, J. R., & Zacksenhaus, E. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1098-z · Cited by 42
Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
Azim, H. A., Ghosn, M. G., Oualla, K., & Kassem, L. M. H. (2019) · The Breast Journal · doi:10.1111/tbj.13713 · Cited by 43
Alcaraz-Sanabria, A. L., Baliu‐Piqué, M., Sáiz-Ladera, C., Rojas, K., Manzano, A., Marquina, G., Casado, A., Cimas, F. J., Pérez‐Segura, P., Pandiella, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01486 · Cited by 43
Major clinical research advances in gynecologic cancer in 2018
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Toftdahl, N. G., Mirza, M. R., & Kim, J. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e18 · Cited by 43
Chumsri, S., Sokol, E. S., Soyano‐Muller, A. E., Parrondo, R. D., Reynolds, G. A., Nassar, A., & Thompson, E. A. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7543 · Cited by 43
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 44
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
Jia, Y., Liu, L., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3735 · Cited by 43
Huang, Q., Zheng, Y., Gao, Z., Yuan, L., Sun, Y., & Chen, H. (2020) · Journal of Cancer · doi:10.7150/jca.49325 · Cited by 44
Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer
Nakhjavani, M., & Shigdar, S. L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106019 · Cited by 42
Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor
Song, D., He, H., Sinha, I., Hases, L., Yan, F., Archer, A., Haldosén, L., Zhao, C., & Williams, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.018 · Cited by 41
Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer
Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S. S., Liu, M., Liang, S., John, E. M., Gomez, S. L., Telli, M. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37636-0 · Cited by 47
“Bilateral mastectomy 93 (14) 14 (12) 107 (14)”
Yin, J., Gu, T., Chaudhry, N. Y., Davidson, N. E., & Huang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1325615 · Cited by 40
“Although breast cancer has been traditionally viewed to be immunologically silent, treatment with ICIs has been shown to improve clinical outcomes in some patients with metastatic BC, especially triple negative breast cancer (TNBC) (16, 17).”
BackgroundTan, T. J., Sammons, S. L., Im, Y., She, L., Mundy, K., Bigelow, R., Traina, T. A., Anders, C. K., Yeong, J. P.-S., Renzulli, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2513 · Cited by 42
The Tumor Immune Microenvironment in Breast Cancer Progression
Fjørtoft, M. O., Huse, K., & Rye, I. H. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.33008 · Cited by 42
Kang, J.-H., Uddin, N., Kim, S., Zhao, Y., Yoo, K.-C., Kim, M., Hong, S.-A., Bae, S., Lee, J., Shin, I., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02150-4 · Cited by 42
Yin, X., Song, X., Deng, W., BLAKE, N. W., Luo, X., & Meng, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483454 · Cited by 44
Hida, A. I., Watanabe, T., Sagara, Y., Kashiwaba, M., Sagara, Y., Aogi, K., Ohi, Y., & Tanimoto, A. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05390-x · Cited by 42
Alsayed, A., Elshenawy, M. A., Tulbah, A. M., Al‐Tweigeri, T., & Ghebeh, H. (2019) · American Journal of Case Reports · doi:10.12659/ajcr.918770 · Cited by 42
Landscape of combination therapy trials in breast cancer brain metastasis
Fares, J., Kanojia, D., Rashidi, A., Ulasov, I. V., & Lesniak, M. S. (2020) · International Journal of Cancer · doi:10.1002/ijc.32937 · Cited by 43
Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer
Li, B., Geng, R., Wu, Q., Yang, Q., Sun, S., Zhu, S., Xu, Z., & Sun, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00333 · Cited by 42
Khan, K. A., de Léon, J. L. P., Benguigui, M., Xu, P., Chow, A., Cruz‐Muñoz, W., Man, S., Shaked, Y., & Kerbel, R. S. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0171-1 · Cited by 42
Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy
Janowitz, T., Kleeman, S., & Vonderheide, R. H. (2021) · The Oncologist · doi:10.1002/onco.13680 · Cited by 42
Han, X., Song, Z., Zhou, Y., Zhang, Y., Deng, Y., Qin, J., Zhang, T., & Jiang, Z. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112054 · Cited by 42
Pérez-García, J. M., Llombart‐Cussac, A., Gión, M., Curigliano, G., López-Miranda, E., Alonso-Romero, J. L., Bermejo, B., Calvo, L., Carañana, V., Sánchez, S. D. L. C., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.028 · Cited by 42
Self-citationYi, H., Li, Y., Tan, Y., Fu, S., Tang, F., & Deng, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648139 · Cited by 43
TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer
Saldías, M. P., Maureira, D., Orellana‐Serradell, O., Silva, I., Lavanderos, B. J., Cruz, P., Torres, C., Cáceres, M., & Cerda, O. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621614 · Cited by 46
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Maritaz, C., Broutin, S., Chaput, N., Marabelle, A., & Paci, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01182-3 · Cited by 45
“In the treatment of triple negative breast cancer, the choice of 840 mg Q2W was not argued for but fits more easily into the nab-paclitaxel regimen [106].”
BackgroundOnagi, H., Horimoto, Y., Sakaguchi, A., Ikarashi, D., Yanagisawa, N., Nakayama, T., Nakatsura, T., Ishizuka, Y., Sasaki, R., Watanabe, J., et al. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01563-7 · Cited by 42
Bayle, A., Khettab, M., Lucibello, F., Chamseddine, A. N., Goldschmidt, V., Perret, A., Ropert, S., Scotté, F., Loulergue, P., & Mir, O. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.290 · Cited by 41
Yang, H., Ren, L., Wang, Y., Bi, X., Li, X., Wen, M., Zhang, Q., Yang, Y., Jia, Y., Li, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03053-0 · Cited by 41
CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
Saleh, L., Wilson, C., & Holen, I. (2021) · MedComm · doi:10.1002/mco2.97 · Cited by 40
A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy
Zhai, Y., Ma, Y., Pang, B., Zhang, J., Li, Y., Rui, Y., Xu, T., Zhao, Y., Qian, Z., Gu, Y., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01193-9 · Cited by 41
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
Yan, T., Yu, L., Shangguan, D., Li, W., Liu, N., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109638 · Cited by 45
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
Ao, Y.-Q., Gao, J., Wang, S., Jiang, J.-H., Deng, J., Wang, H., Xu, B., & Ding, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01772-4 · Cited by 42
Protein nanoparticles as drug delivery systems for cancer theranostics
Hua, Y., Qin, Z., Gao, L., Zhou, M., Xue, Y., Li, Y., & Xie, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.004 · Cited by 42
The treatment landscape of triple-negative breast cancer
Hu, Y., Wang, C., Liang, H., Li, J., & Yang, Q. (2024) · Medical Oncology · doi:10.1007/s12032-024-02456-9 · Cited by 42
Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements
Raman, R., Debata, S., Govindarajan, T., & Kumar, P. (2025) · Cancer Medicine · doi:10.1002/cam4.70803 · Cited by 44
Wei, Y., Du, Q., Jiang, X., Li, L., Li, T., Li, M., Fan, X., Li, Y., Kariminia, S., & Li, Q. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.008 · Cited by 39
Weng, X., Huang, X., Li, H., Lin, S., Rao, X., Guo, X., & Huang, P. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000671 · Cited by 41
Chen, Q., Xia, R., Zheng, W., Zhang, L., Li, P., Sun, X., & Shi, J. (2020) · PubMed Central · Cited by 41
Lee, S., Hu, Y., Loo, S. K., Tan, Y., Bhargava, R., Lewis, M. T., & Wang, X. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921333117 · Cited by 42
Lepland, A., Asciutto, E. K., Malfanti, A., Simón‐Gracia, L., Sidorenko, V., Vicent, M. J., Teesalu, T., & Scodeller, P. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00226 · Cited by 42
Kim, J. S., & Kim, I. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936117 · Cited by 41
Lee, D., Cho, E. J., Lee, J.-H., Yu, S. J., Kim, Y. J., Yoon, J., Kim, T., Han, S., Oh, D., Im, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3094 · Cited by 43
Self-citationBoilève, A., Hilmi, M., Gougis, P., Cohen, R., Rousseau, B., Blanc, J., Abdelghani, M. B., Castanié, H., Dahan, L., Tougeron, D., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.027 · Cited by 41
Setordzi, P., Chang, X., Liu, Z., Wu, Y., & Zuo, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173867 · Cited by 41
Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer
Sobottka, B., Moch, H., & Varga, Z. (2021) · Breast Cancer Research · doi:10.1186/s13058-020-01380-w · Cited by 43
Elimimian, E. B., Samuel, T. A., Liang, H., Elson, L. C., Bilani, N., & Nahleh, Z. A. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4123 · Cited by 41
Breast cancer resistance mechanisms: challenges to immunotherapy
Hanna, A., & Balko, J. M. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06337-x · Cited by 45
Syriac, A. K., Nandu, N. S., & Leone, J. P. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s274514 · Cited by 41
Shemesh, C. S., Chanu, P., Jamsen, K., Wada, R., Rossato, G., Donaldson, F., Garg, A., Winter, H., Ruppel, J., Wang, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0791-x · Cited by 43
Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
Yang, L., Miao, W., He, D., Wang, S., Lou, J., Jiang, Y., & Wang, S. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.680315 · Cited by 40
The advance of adjuvant treatment for triple-negative breast cancer
Ge, J., Zuo, W., Chen, Y., Shao, Z., & Yu, K. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0752 · Cited by 45
Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
Abuhadra, N. K., Stecklein, S. R., Sharma, P., & Moulder, S. L. (2022) · The Oncologist · doi:10.1093/oncolo/oyab003 · Cited by 40
Current Perspectives on Paclitaxel: Focus on Its Production, Delivery and Combination Therapy
Liu, Y., Zhao, F.-L., Wang, Q., Zhao, Q., Hou, G., & Meng, Q. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230210145150 · Cited by 39
Roles and therapeutic implications of m6A modification in cancer immunotherapy
Pan, J., Huang, T., Deng, Z., & Zou, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1132601 · Cited by 39
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030526 · Cited by 43
“0%, whereas hyperthyroidism ranged from 1% to 4% [90,91].”
BackgroundRing, A. E., Kilburn, L., Pearson, A., Moretti, L., Afshari-Mehr, A., Wardley, A. M., Gürel, B., Macpherson, I. R., Riisnaes, R., Baird, R. D., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1696 · Cited by 40
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors
Zhang, C., Peng, K., Liu, Q., Huang, Q., & Liu, T. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104233 · Cited by 43
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review
Panda, V. K., Mishra, B., Mahapatra, S., Swain, B., Malhotra, D., Saha, S., Khanra, S., Mishra, P., Majhi, S., Kumari, K., et al. (2025) · Cancers · doi:10.3390/cancers17020234 · Cited by 47
“The IMpassion130 trial demonstrated the efficacy of treatment with atezolizumab and nab-paclitaxel in extending progression-free survival (PFS) in patients with metastatic TNBC [20].”
Mittendorf, E. A., Assaf, Z. J. F., Harbeck, N., Zhang, H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03725-4 · Cited by 43
Self-citationCollery, P., Veena, V., Harikrishnan, A., & Desmaële, D. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00727-1 · Cited by 40
Pinard, C., Debled, M., Rejeb, H. B., Velasco, V., de Lara, C. T., Hoppe, S., Richard, É., Brouste, V., Bonnefoi, H. R., & MacGrogan, G. M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05437-z · Cited by 40
Qin, T., Xu, X., Zhang, Z., Li, J., You, X., Guo, H.-L., Sun, H., Liu, M., Dai, Z., & Zhu, H. (2020) · Nanotechnology · doi:10.1088/1361-6528/ab94dc · Cited by 40
Metadata
- Authors
- Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., Henschel, V., Molinero, L., Chui, S. Y., Funke, R., Husain, A., Winer, E. P., Loi, S., & Emens, L. A.
- Affiliations
- Queen Mary University of London (GB)
- From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) — both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul,...
- Seoul National University (KR)
- F. Hoffmann-La Roche AG (CH)
- The University of Melbourne (AU)
- Johns Hopkins University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2108-2121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2897422388
- Cited by
- 4,350
- References
- 32
- Citations by year
- 2026: 310 · 2025: 409 · 2024: 453 · 2023: 562 · 2022: 648 · 2021: 825 · 2020: 723 · 2019: 397 · 2018: 17
- FWCI
- 148.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche/Genentech
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- atezolizumab, nab-paclitaxel, triple-negative breast cancer, metastatic breast cancer, PD-L1 expression, immune checkpoint inhibitors, combination chemotherapy, progression-free survival, overall survival, liver metastasis, immune-related adverse events, PD-1/PD-L1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Albumins, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Survival Analysis, Paclitaxel, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
